CoChat

APOE, thought disorder, and SPARE‐AD predict cognitive decline in established Parkinson's disease

Open access
Tropea, Thomas F., Xie, Sharon X., Rick, Jacqueline, Chahine, Lana M., Dahodwala, Nabila, Doshi, Jimit, Davatzikos, Christos, Shaw, Leslie M., Van Deerlin, Vivianna, Trojanowski, John Q., Weintraub, Daniel, Chen‐Plotkin, Alice S. · 2018 · Movement Disorders
Cited by 50

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Background: People with PD are at high risk of developing cognitive impairment and dementia. Cross‐sectional studies have identified candidate biomarkers associated with cognitive decline. However, longitudinal studies on this topic are rarer, and few have investigated the use of biomarker panels encompassing multiple modalities. The objective of this study was to find baseline predictors of cognitive decline in longitudinally followed, nondemented Parkinson's disease patients. Methods: We performed a prospective cohort study of 100 PD patients with a median disease duration of 6.4 years. All participants were nondemented at baseline. We examined 16 baseline biomarkers from clinical, genetic, biochemical, and MRI‐based imaging modalities for their association with longitudinal cognitive decline for up to 8 years. We investigated biomarkers individually, as well as in a multivariate linear mixed‐effects model encompassing multimodal biomarkers, with change in the Mattis Dementia Rating Scale‐2 over time as the primary outcome. Annual consensus process‐derived cognitive diagnosis was used for Cox proportional hazards modeling of risk for cognitive decline. Results: In multivariate analysis, the presence of the APOE E4 allele, thought disorder, and an Alzheimer's disease pattern of brain atrophy (spatial pattern of abnormality for recognition of early Alzheimer's disease index) best predicted cognitive decline, with APOE E4 genotype exerting the greatest effect. The presence of the APOE E4 allele was associated with a 3.5 times higher risk of worsening cognitive diagnosis over time (HR, 3.53; 95% CI, 1.52‐8.24; P < 0.05). The APOE genotype effect was not specific to any Mattis Dementia Rating Scale‐2 domain. Conclusions: Our results confirm the importance of Alzheimer's disease biomarkers as risk factors for cognitive decline in established Parkinson's disease. © 2017 International Parkinson and Movement Disorder Society

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/mds.27204

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 50

Metadata

Authors
Tropea, T. F., Xie, S. X., Rick, J., Chahine, L. M., Dahodwala, N., Doshi, J., Davatzikos, C., Shaw, L. M., Van Deerlin, V., Trojanowski, J. Q., Weintraub, D., & Chen‐Plotkin, A. S.
Venue
Movement Disorders
Publisher
Wiley
Published
2017-11-23
Volume
33
Issue
2
Pages
289-297
ISSN
  • 0885-3185 (ISSN-L)
  • 1531-8257
OpenAlex
W2770569755
Cited by
50
References
14
FWCI
2.93
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: APOE, thought disorder, and SPARE‐AD predict cognitive decline in established Parkinson's disease. https://app.cochat.ai/papers/10.1002/mds.27204
The paper
Tropea, T. F., Xie, S. X., Rick, J., Chahine, L. M., Dahodwala, N., Doshi, J., Davatzikos, C., Shaw, L. M., Van Deerlin, V., Trojanowski, J. Q., Weintraub, D., & Chen‐Plotkin, A. S. (2018). APOE, thought disorder, and SPARE‐AD predict cognitive decline in established Parkinson's disease. Movement Disorders. https://doi.org/10.1002/mds.27204

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.